- Home
- GNLX vs HLVX Comparison
GNLX vs HLVX Comparison
Compare GNLX & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- HLVX
- Stock Information
- Founded
- GNLX 2001
- HLVX 2020
- Country
- GNLX United States
- HLVX United States
- Employees
- GNLX N/A
- HLVX N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- GNLX Health Care
- HLVX Health Care
- Exchange
- GNLX Nasdaq
- HLVX Nasdaq
- Market Cap
- GNLX 129.9M
- HLVX 105.2M
- IPO Year
- GNLX 2023
- HLVX 2022
- Fundamental
- Price
- GNLX $3.53
- HLVX $2.09
- Analyst Decision
- GNLX Strong Buy
- HLVX Hold
- Analyst Count
- GNLX 5
- HLVX 1
- Target Price
- GNLX $16.20
- HLVX $2.00
- AVG Volume (30 Days)
- GNLX 153.8K
- HLVX 136.7K
- Earning Date
- GNLX 08-13-2025
- HLVX 08-11-2025
- Dividend Yield
- GNLX N/A
- HLVX N/A
- EPS Growth
- GNLX N/A
- HLVX N/A
- EPS
- GNLX N/A
- HLVX N/A
- Revenue
- GNLX N/A
- HLVX N/A
- Revenue This Year
- GNLX N/A
- HLVX N/A
- Revenue Next Year
- GNLX N/A
- HLVX N/A
- P/E Ratio
- GNLX N/A
- HLVX N/A
- Revenue Growth
- GNLX N/A
- HLVX N/A
- 52 Week Low
- GNLX $1.60
- HLVX $1.34
- 52 Week High
- GNLX $5.89
- HLVX $2.17
- Technical
- Relative Strength Index (RSI)
- GNLX 58.36
- HLVX 53.35
- Support Level
- GNLX $3.30
- HLVX $2.07
- Resistance Level
- GNLX $3.60
- HLVX $2.17
- Average True Range (ATR)
- GNLX 0.26
- HLVX 0.07
- MACD
- GNLX 0.00
- HLVX -0.01
- Stochastic Oscillator
- GNLX 75.71
- HLVX 42.86
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.